| Immunoglobulin Mu Binding Protein 2 | |
|---|---|
| Gene | IGHMBP2 |
| UniProt | Q9UHK6 |
| PDB | 6GMH, 6GMI |
| Mol. Weight | 105 kDa |
| Localization | Nucleus, Cytoplasm |
| Family | SF1 helicase superfamily |
| Diseases | Spinal Muscular Atrophy with Respiratory Distress (SMARD1), Amyotrophic Lateral Sclerosis (ALS) |
Immunoglobulin Mu Binding Protein 2 (IGHMBP2) is a DNA/RNA helicase encoded by the IGHMBP2 gene on chromosome 11q13.3. It belongs to the SF1 helicase superfamily and possesses ATP-dependent DNA and RNA helicase activities, as well as ATPase activity. The protein is approximately 105 kDa and localizes to both the nucleus and cytoplasm of cells.
IGHMBP2 is critically involved in motor neuron development and function. Mutations in IGHMBP2 cause Spinal Muscular Atrophy with Respiratory Distress type 1 (SMARD1), a severe autosomal recessive neuromuscular disorder characterized by progressive motor neuron degeneration, diaphragmatic paralysis, and respiratory failure [1].
IGHMBP2 contains several key structural domains:
Crystal structures of the helicase domain have been solved (PDB: 6GMH, 6GMI), revealing the structural basis for ATP hydrolysis and helicase activity [2]. The protein can also be explored via the AlphaFold Protein Structure Database.
Under physiological conditions, IGHMBP2 performs several essential functions:
IGHMBP2 acts as a transcription factor, binding to the immunoglobulin μ chain enhancer region and regulating gene expression involved in neuronal development and survival [3].
The helicase activity of IGHMBP2 participates in DNA repair pathways, maintaining genomic integrity in neuronal cells [4].
IGHMBP2 is involved in RNA processing and splicing, particularly for genes critical to motor neuron function [5].
Recent studies suggest IGHMBP2 plays a role in mitochondrial dynamics and energy metabolism in motor neurons [6].
SMARD1 (also known as SMARD1 or distal spinal muscular atrophy type 1) is caused by recessive mutations in the IGHMBP2 gene. The disease typically presents in early infancy with:
Over 100 pathogenic IGHMBP2 mutations have been identified, including missense, nonsense, splice-site, and frameshift mutations. Genotype-phenotype correlations show that null mutations cause more severe disease than missense mutations that retain partial function [7].
IGHMBP2 has been implicated in ALS pathogenesis:
The loss of functional IGHMBP2 leads to neurodegeneration through multiple mechanisms:
IGHMBP2 represents an important therapeutic target for SMARD1 and related disorders: